Development of an L6 myoblast in vitro model of moniliformin toxicosis

Mycopathologia

Volumn 133, Issue 2, 1996, Pages 105-114

  Reams, R ^a   Thacker, H L ^a   Novilla, M ^c   Laska, D ^c   Horn, J ^c   Harrington, D ^a   Greenlee, W ^b   Vesonder, R ^d  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d NATIONAL CENTER FOR AGRICULTURAL UTILIZATION RESEARCH   (United States)

Author keywords

A23187; beauvericin; L6 myoblast; monensin; moniliformin; pyruvate dehydrogenase

Indexed keywords

ANIMALIA; AVES; MELEAGRIS GALLOPAVO;

EID: 0029758902     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00439121     Document Type: Article

References (19)

1. Abbas HK, Mirocha CJ, Vesonder RF, Gunther R. Acute toxic effects of an isolate of moniliformin-producing Fusarium oxysporum and purified moniliformin on rats. Arch Environ Contam Toxicol 1990; 19: 433-436.
2. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. The plasma membrane. In: Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD (eds). The Cell. New York, NY: Garland Publishing, Inc., 1989: 275-340.
3. Blass JP, Kark RAP, Engel WK. Clinical studies of a patient with pyruvate decarboxylase deficiency. Arch Neurol 1971; 25: 449-460.
4. Burka LT, Doran J, Wilson BJ. Enzyme inhibition and the toxic action of moniliformin and other vinylogous a ketoacids. Biochem Pharmacol 1982; 31: 79-84.
5. Burmeister HR, Ciegler A, Vesonder RF. Moniliformin, a metabolite of Fusarium moniliforme NRRL 6322: Purification and toxicity. Appl Environ Microbiol 1979; 37: 11-13.
6. Burmeister HR, Grove MD, Kwolek WF. Moniliformin and butenolide: Effect on mice of high-level, long-term oral intake. Appl Environ Microbiol 1980; 40: 1142-1144.
7. Cardona CJ, Galey FD, Bickford AA, Charlton BR, Cooper GL. Skeletal muscle myopathy produced with experimental dosing of turkeys with monensin. Avian Dis 1993; 37: 107-117.
8. Chen L, Tian X, Yang B. A study on the inhibition of rat myocardium glutathione peroxidase and glutathione reductase by moniliformin. Mycopathologia 1990; 110: 119-124.
9. Cheville NF. Blockade of metabolic pathways. In: Cheville NF (ed.), Ultrastructural pathology. Ames, Iowa: Iowa State University Press. 1994: 126-191.
10. Cheville NF. Interpretation of acute cellular injury and degeneration. In: Cheville NF (ed), Ultrastructural patholog. Ames, Iowa: Iowa State University Press, 1994: 51-76.
11. Cole RJ, Kirksey JW, Cutler HG, Doupnik BL, Peckham JC. Toxin from Fusarium moniliforme: effects on plants and animals. Science 1973; 179: 1324-1326.
12. Dawson M. Initiation and maintenance of cultures. In: Butler M, Dawson M (eds), Cell Culture. Oxford, UK: Bios Scientific Publishers Limited, 1992: 25-42.
13. De Vivo DC. The expanding clinical spectrum of mitochondrial disease. Brain Develop 1993; 15: 1-22.
14. Deyu Z, Qi F, Xianghzen Y, Chenghe L, Van P, Qin C. Ultrastructural study of moniliformin induced lesions of myocardium in rats and mice. Biomed Environ Sci 1993; 6: 37-44.
15. DuBourdieu DJ, Shier WT, Sodium- and calcium-dependent steps in the mechanism of neonatal rat cardiac myocyte killing by ionophores. II. The calcium-carrying ionophore, A23187. Toxicol Appl Pharmacol 1992; 116: 47-56.
16. Emeteria Y, Roddy F, Yount RG, Metzler DE. The catalytic decarboxylation of pyruvate by thiamine. J Biol Chem 1958; 234: 733-737.
17. Engelhardt JA, Carlton WW, Tuite JF. Toxicity of Fusarium moniliforme var. subglutinans in chicks, ducklings and turkey poults. Avian Dis 1989; 33: 357-360.
18. Frank RK, Newman J, Ruth GR. Lesions of perirenal hemorrhagic syndrome in growing turkeys. Avian Dis 1991; 35: 523-534.
19. Gathercole PS, Thiel PG, Hofmeyr JHS. Inhibition of pyruvate dehydrogenase complex by moniliformin. Biochem J 1986; 233: 719-723.